Acarix A/S vs Abbott Laboratories: Fair Value & Quality
Both stocks run through our valuation models. Here is how Acarix A/S (ACARIX) and Abbott Laboratories (ABT) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Acarix A/S trades at SEK 0.25 versus a fair value of SEK 0.03 (-90%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Acarix A/S
ACARIX.ST · SEK · Health Care
-90%
upside to fair value
overvalued
PriceSEK 0.25
Fair ValueSEK 0.03
Quality35/100
Abbott Laboratories
ABT · USD · Health Care
-31%
upside to fair value
overvalued
Price$108
Fair Value$74.79
Quality67/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Acarix A/SAbbott Laboratories
Valuation
—P/E (TTM)27.7×
3.90×P/S (TTM)3.89×
0.82×P/B3.36×
—EV/EBITDA15.1×
—PEG1.47×
Profitability
0%Net margin14%
—Operating margin13%
-88%Return on equity12%
-49%Return on assets6%
Growth
40%Revenue growth (YoY)8%
8.1%Avg. growth/yr (3Y)0.5%
27.7%Avg. growth/yr (5Y)5.1%
Balance & size
—Debt / equity0.19×
$31MMarket cap$175B
mixedGrowth qualityhealthy
Even match: 4 to 4 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Acarix A/Sof which business quality 35 · market factors 33Abbott Laboratoriesof which business quality 66 · market factors 51
ProfitabilityMargins and returns on capital today
2
50
Quality GrowthAre margins and returns improving?
53
47
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
85
65
Low VolatilityCalm price path (market factor)
68
83
MomentumPrice trend over the last 3–12 months (market factor)
26
40
52W MomentumDistance to the 52-week high (market factor)
6
33
Net IssuanceBuybacks instead of dilution
0
84
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Acarix A/S
Asset-BasedSEK 0.02
1 of 1 models see the stock below the current price.
Abbott Laboratories
DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Acarix A/S
Bear SEK 0.02Fair Value SEK 0.03Bull SEK 0.03
SEK 0.25 = current price (white tick)
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$108 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Acarix A/S · Health Care
Quality score35 · bottom 25%
Fair value upside-90% · bottom 25%
Abbott Laboratories · Health Care
Quality score67 · Top 25%
Fair value upside-31% · below median
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Acarix A/S trades at SEK 0.25 versus a fair value of SEK 0.03 (-90%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Abbott Laboratories has the higher quality score (67/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
